ImmunoPrecise Antibodies (IPA) Projected to Post Quarterly Earnings on Tuesday

ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) is projected to release its Q4 2025 earnings data before the market opens on Tuesday, July 29th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $7.89 million for the quarter.

ImmunoPrecise Antibodies Stock Performance

Shares of NASDAQ IPA traded up $0.12 during mid-day trading on Wednesday, hitting $1.82. The company had a trading volume of 929,076 shares, compared to its average volume of 2,629,091. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.32 and a quick ratio of 2.11. The business's 50-day simple moving average is $0.95 and its 200-day simple moving average is $0.62. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $2.32. The firm has a market cap of $83.29 million, a P/E ratio of -1.57 and a beta of 0.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of ImmunoPrecise Antibodies to a "sell" rating in a report on Saturday, May 24th. Benchmark restated a "speculative buy" rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research report on Tuesday, April 1st. Finally, HC Wainwright restated a "buy" rating and set a $5.00 target price on shares of ImmunoPrecise Antibodies in a research report on Friday, April 11th.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.